Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Claire N. Harrison,John Mascarenhas,Pranav Abraham,Arianna Kee,Jose Alberto Nadal,Alexandrina Balanean,Ali McBride,Jonathan K. Kish,Djibril Liassou,Bruce A. Feinberg,Aaron T. Gerds

Blood（2021）

引用 1|浏览3

暂无评分

摘要

Introduction: In August 2019, fedratinib (FEDR) became the second treatment (in addition to ruxolitinib [RUX]) to be approved for intermediate- or high-risk primary or secondary myelofibrosis (MF). No real-world data (RWD) have been presented on demographics, clinical characteristics, and treatment patterns of FEDR for patients receiving FEDR per US label post RUX failure.

查看译文

关键词

fedratinib,real-world,post-ruxolitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要